Gilead Sciences has announced the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in the US.
This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 billion investment in US innovation through 2030.
This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing.
The five-story, 180,000 square foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry.
The new facility will strengthen Gilead’s biologics capacity and capabilities, a central pillar of the company’s growth strategy. This investment builds on Gilead’s broader US efforts to expand research and manufacturing, create more than 3,000 direct and indirect high-quality jobs, and advance equitable access to healthcare nationwide.
